Pharmaceutical Technology

MAY 2, 2023

The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. This newly granted status helps Erasca to facilitate the development and review of ERAS-801, thereby accelerating the therapy’s reach to patients.

Bioavailability 130

Bioavailability Clinical Development Gene Trials 130

Pharmaceutical Technology

JANUARY 17, 2023

OR-449 is a first-in-class, orally bioavailable, potent and selective small molecule antagonist of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1). SF-1 is an important transcription factor for adrenal gland growth and development. The company is developing OR-449 to treat ACC in adult and paediatric patients.

Bioavailability 147

Bioavailability Clinical Trials Clinical Trials Clinical Development 147

Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.

Medicine 52

Medicine Bioavailability Clinical Development Trials 52

XTalks

DECEMBER 5, 2022

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2

Bioavailability 97

Bioavailability FDA Approval Trials Drugs 97

Drug Discovery World

JULY 25, 2023

Justin Hay , Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects. The guidance mentions PBPK four times regarding renal function and DDIs.

Development 52

Development Drugs Medicine Production 52

Drug Discovery World

APRIL 8, 2024

It is progressing to Phase I clinical trials with JD Bioscience. In response to the pressing need of effective treatments for these metabolic disorders, researchers led by Professor Jin Hee Ahn from Gwangju Institute of Science and Technology (GIST) meticulously developed compound 11c, a novel peripheral 5HT2A antagonist.

Drugs 52

Drugs Bioavailability Clinical Trials Clinical Trials 52

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Proper planning of PK assessments can accelerate the development of both novel drugs and new formulations of previously approved drugs developed via the 505(b)(2) pathway.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

Drug Discovery World

MARCH 3, 2023

Trial design The placebo-controlled, Phase IIa, proof-of-concept trial will evaluate short-term changes in anxiety-related patient reported outcomes in approximately 50 healthy volunteers. The trial will be conducted using a validated clinical model that simulates social anxiety.

Bioavailability 52

Bioavailability Trials Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 27, 2023

Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met inhibitor. It works by inhibiting the aberrant activation of the HGF/c-Met axis, a key pathway involved in tumour growth, proliferation, and the development of resistance to certain targeted therapies.

Bioavailability 52

Bioavailability Clinical Trials Clinical Trials Trials 52

Drug Discovery World

JULY 27, 2022

Recursion’s therapy REC-4881 is an orally bioavailable non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in FAP patients. . FAP is a rare tumour syndrome in which hundreds or thousands of precancerous colorectal polyps grow in the body.

Bioavailability 52

Bioavailability Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round. .

RNA 52

RNA Immune Response Bioavailability Development 52

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Clinical Pharmacology. Clinical Safety and Efficacy.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 8, 2021

We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Pharmaceutical Technology

JANUARY 25, 2023

Development of PROTACs (PROteolysis TArgeting Chimeras) has advanced fairly rapidly as excitement grows over their potential to selectively degrade proteins that are involved in various diseases, including cancer. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.

Protein 130

Protein Bioavailability Development Scientist 130

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. Along with knee osteoarthritis, Grünenthal also plans to test resiniferatoxin in other joints affected by the condition.

Drugs 52

Drugs Bioavailability Trials Clinical Development 52

Roots Analysis

MARCH 2, 2022

Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

XTalks

FEBRUARY 3, 2023

Aditya Bardia, MD, MPH, director of Breast Cancer Research at Mass General Cancer Center, associate professor at the Medicine Department at Harvard Medical School and principal investigator for the EMERALD trial, in the same press release statement. Orserdu is available in the form of 345 mg tablets to be taken once a day with food.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. vice president of immunology development at Lilly.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

DECEMBER 1, 2020

NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the open-label Phase 2 COMET-TRD trial of AXS-05 in patients with treatment resistant depression (TRD). AXS-05 was well tolerated in the COMET trial.

Trials 52

Trials Clinical Trials Clinical Trials Production 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

XTalks

JUNE 14, 2023

The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis”, said John D. “The Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

pharmaphorum

JANUARY 16, 2023

They include a once-monthly form of paliperidone called LY03010 that has shown comparable bioavailability with Johnson & Johnson’s Invega Sustenna in a pivotal trial and has a slightly simpler regimen in the induction therapy stage.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company NRG Therapeutics Ltd., It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

XTalks

APRIL 11, 2023

Most people typically develop Parkinson’s disease after the age of 60, and early onset forms of Parkinson’s disease are often inherited, though some forms may be linked to genetic mutations or exposure to environmental toxins like pesticides. Anticholinergic medication can help reduce tremors and muscle stiffness.

Bioavailability 98

Bioavailability Genetics Nurses Development 98

The Pharma Data

DECEMBER 29, 2020

Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Life Science 52

Life Science Bioavailability Clinical Trials Clinical Trials 52

Delveinsight

JANUARY 7, 2021

Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. Why is it Difficult to Develop CNS Therapeutics? During the webinar, Dr. Vornov discussed a few developments in targeted CNS delivery, which are summarized below.

Trials 83

Trials Drug Delivery Drugs Gene 83

Delveinsight

FEBRUARY 16, 2021

The drug is the first and only therapy that is developed and approved to protect bone marrow (myeloprotection), which is injected prior to treatment with chemotherapy, asserts the US oncology drug developer, G1. Maribavir is an orally bioavailable anti-CMV compound.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Roots Analysis

SEPTEMBER 1, 2023

The integration of the blue ocean strategy in healthcare landscape, often known as blue ocean therapy, and its application in medical product development, such as blue ocean medical products, is the silver lining that can revolutionize the industry. This strategy is not a silver bullet; it’s a calculated voyage into uncharted waters.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

Delveinsight

AUGUST 10, 2020

Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Ofev (Nintedanib) Facts.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

The Pharma Data

NOVEMBER 22, 2020

The new patent applications are the outcome of years of high-quality research engaged by Alzprotect and highlight the company’s commitment to the development Ezeprogind.”. Alzprotect imagines and develops therapeutic solutions to slow down or stop neurodegenerative diseases and restore patients’ brain capacity. 23, 2020 10:33 UTC.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

OCTOBER 9, 2021

Both recommendations were based on the results of the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trials. The NDA submission is based on the pivotal Phase 3 TAK-620-303 (SOLSTICE) trial. Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the U.S. About maribavir.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

The Pharma Data

MARCH 11, 2021

Additionally, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, will present preclinical characterization data for an oral selective estrogen receptor degrader (SERD), BCL2 inhibitor, next-generation KRAS-G12C inhibitor, and next-generation RET inhibitor. Session Type: Clinical Trials Plenary Session.

Research 52

Research Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

FEBRUARY 13, 2023

The continued high level of interest in small molecules presents multiple opportunities to select a candidate that is ‘developable’, with subsequent rapid progression toward first-in-human (FIH) clinical testing. Therefore, it is vital to choose molecules for pharmaceutical development very carefully.

Development 130

Development In-Vivo Clinical Trials Clinical Trials 130

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52